Thomas Decaens

14.1k citations
197 papers · 10.9k · 9 hit papers · h-index 40

Impact in

  • Hepatology top 0.05%
    • Hepatocellular Carcinoma Treatment and Prognosis
    • Liver physiology and pathology
    • Cancer Genomics and Diagnostics

Papers in

    • Hepatocellular Carcinoma Treatment and Prognosis 121
    • Liver physiology and pathology 9
    • Hepatitis C virus research 8
    • Liver Disease Diagnosis and Treatment 12
    • Hepatitis B Virus Studies 9

Thomas Decaens

180 papers receiving 10.6k citations

Thomas Decaens's Hit Papers

Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study 2025 · 151 citations
1510+5+10Years since publication5001k1.5k

Peers

Thomas Decaens
Comparison fields: 5 of 119
  • Hepatology 6.2k
  • Cancer Research 1.2k
  • Oncology 1k
  • Molecular Biology 1.8k
  • Epidemiology 651
Replace Jean‐Charles Nault with:
Jean‐Charles Nault France
Daniela Sia United States
Rongcheng Luo China
Zhao–You Tang China
Éric Letouzé France
Sasan Roayaie United States
Jesper Bøje Andersen Denmark
Marshonna Forgues United States
Ahmed Omar Kaseb United States
Sanjay Kakar United States
Thomas Decaens relative to Jean‐Charles Nault France Jean‐Charles Nault's profile →
Citations per field
00.5×1.5×
Jean‐Charles Nault · 1×
Citations per year

Countries citing papers authored by Thomas Decaens

Since Specialization
Citations

This map shows the geographic impact of Thomas Decaens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Decaens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Decaens more than expected).

Fields of papers citing papers by Thomas Decaens

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Decaens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Decaens. The network helps show where Thomas Decaens may publish in the future.

Co-authors

The 25 scholars most cited alongside Thomas Decaens, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thomas Decaens Line = papers co-authored together Thomas Decaens links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 197 papers — load more, or switch the sort, to bring in the rest.

#Work
1
International network of cancer genome projects
Hit paper breakdown →
20101844
2
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Hit paper breakdown →
20211029
3
Liver Transplantation for Hepatocellular Carcinoma: A Model Including α-Fetoprotein Improves the Performance of Milan Criteria
Hit paper breakdown →
2012780
4
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
Hit paper breakdown →
2013664
5
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
Hit paper breakdown →
2013517
6 2006441
7
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
Hit paper breakdown →
2023374
8
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
Hit paper breakdown →
2018308
9 2013281
10 2013277
11 2004276
12 2009245
13 2017205
14 2017195
15 2005175
16
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
Hit paper breakdown →
2025161
17
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
Hit paper breakdown →
2025151
18 2006138
19 2007138
20 2014107

About Thomas Decaens

Thomas Decaens is a scholar working on Hepatology, Epidemiology, Oncology, Immunology and Surgery, having authored 197 papers that have together received 10.9k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (121 papers), Liver Disease Diagnosis and Treatment (12 papers), Cancer Immunotherapy and Biomarkers (10 papers), Hepatitis B Virus Studies (9 papers), Organ Transplantation Techniques and Outcomes (9 papers), Liver physiology and pathology (9 papers), Hepatitis C virus research (8 papers) and Wnt/β-catenin signaling in development and cancer (7 papers). The work is most often cited by research in Hepatology (6.2k citations), Cancer Research (1.2k citations), Oncology (1k citations), Molecular Biology (1.8k citations) and Epidemiology (651 citations). Thomas Decaens has collaborated with scholars based in France, United States and Germany. Frequent co-authors include Zuzana Macek Jílková, Sabine Colnot, Christine Perret, Cécile Godard, Alexis Laurent, Christophe Duvoux, Axel Kahn, Jesper Bøje Andersen, Snorri S. Thorgeirsson and Matthias Sebastian Matter. Their work appears in journals such as Journal of Hepatology, Annals of Oncology, Liver International, JHEP Reports and Hepatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact